Upgrade to SI Premium - Free Trial

Ascendis Pharma (ASND)

270.56 -0.56 (0.21%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer September 1, 2026 4:04 PM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $273 at Morgan Stanley September 1, 2026 8:07 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities September 1, 2026 6:59 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $330 at Jefferies August 31, 2026 8:51 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $326 at Stifel August 31, 2026 8:10 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND) August 31, 2026 6:49 AM - StreetInsider H.C. Wainwright Starts Ascendis Pharma (ASND) at Buy August 27, 2026 6:12 AM - StreetInsider Ascendis to present 2-year navepegritide trial data at ISDS 2026 August 25, 2026 4:01 PM - StreetInsider Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 August 25, 2026 4:01 PM - Globe NewsWire Form 4 Ascendis Pharma A/S For: Aug 14 Filed by: BIENAIME JEAN JACQUES August 18, 2026 9:03 PM - SEC Filing BMO Capital Starts Ascendis Pharma (ASND) at Outperform August 18, 2026 4:13 PM - StreetInsider Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients August 18, 2026 8:00 AM - StreetInsider Ascendis Pharma (ASND) PT Raised to $341 at TD Cowen August 14, 2026 8:50 AM - StreetInsider Ascendis Pharma (ASND) PT Raised to $290 at RBC Capital August 14, 2026 8:41 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $329 at Barclays August 14, 2026 4:20 AM - StreetInsider Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: Artisan Partners Limited Partnership August 13, 2026 4:31 PM - SEC Filing Ascendis Pharma (ASND) PT Raised to $360 at Citi August 13, 2026 4:08 PM - StreetInsider Ascendis Pharma (ASND) PT Raised to $333 at Jefferies August 13, 2026 4:03 PM - StreetInsider Form 6-K Ascendis Pharma A/S For: Aug 13 August 13, 2026 9:14 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: Jun 30 August 13, 2026 7:56 AM - SEC Filing Ascendis Pharma (ASND) Tops Q2 EPS by 132c August 13, 2026 7:41 AM - StreetInsider Ascendis Pharma Reports Second Quarter 2026 Financial Results August 13, 2026 7:30 AM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Aug 12 August 12, 2026 5:16 PM - SEC Filing Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 August 6, 2026 4:01 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Aug 06 August 6, 2026 11:55 AM - SEC Filing Ascendis reports COACH trial Week 78 data and Yuviwel uptake August 6, 2026 8:01 AM - StreetInsider Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. August 6, 2026 8:00 AM - Globe NewsWire Ascendis Pharma (ASND) PT Raised to $275 at Morgan Stanley July 23, 2026 8:42 AM - StreetInsider Form 6-K Ascendis Pharma A/S For: Jul 15 July 15, 2026 4:57 PM - SEC Filing Ascendis Pharma (ASND) PT Raised to $306 at BofA Securities July 14, 2026 6:03 AM - StreetInsider Ascendis Pharma (ASND) PT Raised to $280 at RBC Capital July 7, 2026 7:59 AM - StreetInsider Form 6-K Ascendis Pharma A/S For: Jun 30 June 30, 2026 4:06 PM - SEC Filing Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial June 30, 2026 8:30 AM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Jun 29 June 29, 2026 4:05 PM - SEC Filing Ascendis Pharma added to Russell 1000 and other indexes June 26, 2026 4:01 PM - StreetInsider Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® June 26, 2026 4:01 PM - Globe NewsWire Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 June 25, 2026 4:01 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Jun 17 June 17, 2026 4:48 PM - SEC Filing Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND) June 15, 2026 7:07 AM - StreetInsider Form 6-K Ascendis Pharma A/S For: Jun 15 June 15, 2026 6:16 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: Jun 12 June 12, 2026 6:04 AM - SEC Filing Ascendis reports 5-year TransCon PTH data in hypoparathyroidism patients June 11, 2026 4:01 PM - StreetInsider 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism June 11, 2026 4:01 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Jun 10 June 10, 2026 4:09 PM - SEC Filing Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND) June 9, 2026 6:51 AM - StreetInsider Full Article List